文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

基于甲病毒的癌症免疫治疗载体驱动的巨噬细胞转录组改变

Macrophage Transcriptomic Alterations Driven by Alphavirus-Based Cancer Immunotherapy Vectors.

作者信息

Korotkaja Ksenija, Lapina Darija, Rudevica Zhanna, Zajakina Anna

机构信息

Cancer Gene Therapy Group, Latvian Biomedical Research and Study Centre, Ratsupites Str. 1 k. 1, Riga LV-1067, Latvia.

出版信息

J Immunol Res. 2025 Jun 13;2025:6573891. doi: 10.1155/jimr/6573891. eCollection 2025.


DOI:10.1155/jimr/6573891
PMID:40547518
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12181664/
Abstract

Cancer cells promote the polarisation of tumour-associated macrophages (TAMs) into pro-tumorigenic M2-like phenotype, contributing to cancer progression. Reprogramming TAMs by viral immunotherapy vectors represents a promising strategy for cancer therapy. However, the factors driving macrophage reprogramming into a tumour-suppressing M1-like phenotype in response to viral vectors remain unclear. Alphaviral vectors, such as Semliki Forest virus (SFV), indirectly influence macrophages through cancer cell infection, cytokine gene delivery and tumour microenvironment (TME) modulation. This study examines macrophage transcriptomic alterations induced by SFV vectors. Murine mammary cancer cells were infected with SFV delivering tumour necrosis factor-α (TNFα) or interferon-γ (IFNγ) genes. Conditioned media from infected cells were used to treat bone marrow-derived macrophages (BMDMs) with subsequent analysis of the transcriptome. As a result, SFV-infected cancer cells significantly altered cytokine and chemokine profiles, reducing immunosuppressive factors (e.g., IL-10) and increasing inflammatory mediators (e.g., CXCL10 and CCL4). RNA sequencing revealed upregulation of genes associated with antigen presentation, interferon responses and M1 polarisation in macrophages treated with SFV/TNFα and SFV/IFNγ-conditioned media. SFV/IFNγ inhibited cancer-associated pathways (angiogenesis, glycolysis and extracellular matrix (ECM) remodelling) and enhanced cytotoxic lymphocyte (CTL) chemoattractants (CXCL9 and CXCL10). SFV/TNFα selectively upregulated , and . All SFV vectors upregulated PD-L1 () expression. The study demonstrates that alphavirus-mediated gene delivery to cancer cells can impact macrophages, inducing proinflammatory responses and reprogramming them into anti-cancer phenotype. However, combining SFV/IFNγ with immune checkpoint inhibitors could potentially improve therapeutic efficacy by mitigating virus-induced suppressive signals in the TME.

摘要

癌细胞促使肿瘤相关巨噬细胞(TAM)极化为促肿瘤的M2样表型,从而推动癌症进展。通过病毒免疫治疗载体对TAM进行重编程是一种很有前景的癌症治疗策略。然而,响应病毒载体促使巨噬细胞重编程为具有肿瘤抑制作用的M1样表型的驱动因素仍不清楚。诸如辛德毕斯病毒(SFV)等甲病毒载体通过癌细胞感染、细胞因子基因传递和肿瘤微环境(TME)调节间接影响巨噬细胞。本研究检测了SFV载体诱导的巨噬细胞转录组变化。用携带肿瘤坏死因子-α(TNFα)或干扰素-γ(IFNγ)基因的SFV感染小鼠乳腺癌细胞。用感染细胞的条件培养基处理骨髓来源的巨噬细胞(BMDM),随后对转录组进行分析。结果,感染SFV的癌细胞显著改变了细胞因子和趋化因子谱,减少了免疫抑制因子(如IL-10)并增加了炎症介质(如CXCL10和CCL4)。RNA测序显示,在用SFV/TNFα和SFV/IFNγ条件培养基处理的巨噬细胞中,与抗原呈递、干扰素反应和M1极化相关的基因上调。SFV/IFNγ抑制了癌症相关途径(血管生成、糖酵解和细胞外基质(ECM)重塑)并增强了细胞毒性淋巴细胞(CTL)趋化因子(CXCL9和CXCL10)。SFV/TNFα选择性地上调了 、 和 。所有SFV载体均上调了PD-L1( )的表达。该研究表明,甲病毒介导的向癌细胞的基因传递可影响巨噬细胞,诱导促炎反应并将它们重编程为抗癌表型。然而,将SFV/IFNγ与免疫检查点抑制剂联合使用可能通过减轻TME中病毒诱导的抑制信号来潜在地提高治疗效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bcc/12181664/b6dfb070f5fa/JIR2025-6573891.011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bcc/12181664/7674a3d6896e/JIR2025-6573891.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bcc/12181664/c571d0094310/JIR2025-6573891.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bcc/12181664/16e01111e9b5/JIR2025-6573891.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bcc/12181664/1b7e89212a7e/JIR2025-6573891.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bcc/12181664/986a840f436c/JIR2025-6573891.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bcc/12181664/e2ce90feb24d/JIR2025-6573891.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bcc/12181664/c915cb7f6eb2/JIR2025-6573891.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bcc/12181664/e9641e7bab56/JIR2025-6573891.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bcc/12181664/39388ec708ad/JIR2025-6573891.009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bcc/12181664/4b7d1c0291cd/JIR2025-6573891.010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bcc/12181664/b6dfb070f5fa/JIR2025-6573891.011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bcc/12181664/7674a3d6896e/JIR2025-6573891.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bcc/12181664/c571d0094310/JIR2025-6573891.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bcc/12181664/16e01111e9b5/JIR2025-6573891.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bcc/12181664/1b7e89212a7e/JIR2025-6573891.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bcc/12181664/986a840f436c/JIR2025-6573891.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bcc/12181664/e2ce90feb24d/JIR2025-6573891.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bcc/12181664/c915cb7f6eb2/JIR2025-6573891.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bcc/12181664/e9641e7bab56/JIR2025-6573891.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bcc/12181664/39388ec708ad/JIR2025-6573891.009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bcc/12181664/4b7d1c0291cd/JIR2025-6573891.010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bcc/12181664/b6dfb070f5fa/JIR2025-6573891.011.jpg

相似文献

[1]
Macrophage Transcriptomic Alterations Driven by Alphavirus-Based Cancer Immunotherapy Vectors.

J Immunol Res. 2025-6-13

[2]
Systemic treatments for metastatic cutaneous melanoma.

Cochrane Database Syst Rev. 2018-2-6

[3]
Integrating multi-omics data to optimize immunotherapy in endometrial cancer: a comprehensive study.

Discov Oncol. 2025-6-20

[4]
Reprogramming Tumor-Associated Macrophage by Ornithine Decarboxylase Inhibitor and Immune Checkpoint for Orthotopic Glioblastoma Photothermal Immunotherapy.

ACS Appl Mater Interfaces. 2025-6-18

[5]
VSIG4 as a tumor-associated macrophage marker predicting adverse prognosis in diffuse large B-cell lymphoma.

Front Immunol. 2025-6-5

[6]
Tumor-derived CD109 orchestrates reprogramming of tumor-associated macrophages to dampen immune response.

J Hepatol. 2025-4-11

[7]
Blocking ITGA5 potentiates the efficacy of anti-PD-1 therapy on glioblastoma by remodeling tumor-associated macrophages.

Cancer Commun (Lond). 2025-3-14

[8]
The co-location of MARCO+ tumor-associated macrophages and CTSE+ tumor cells determined the poor prognosis in intrahepatic cholangiocarcinoma.

Hepatology. 2025-7-1

[9]
ISCU-p53 axis orchestrates macrophage polarization to dictate immunotherapy response in esophageal squamous cell carcinoma.

Cell Death Dis. 2025-6-20

[10]
Novel fusion superkine, , enhances immunotherapy of brain cancer.

J Immunother Cancer. 2025-6-22

引用本文的文献

[1]
Tumor-infiltrating lymphocytes in NSCLC: from immune surveillance to immunotherapy.

Front Immunol. 2025-7-25

本文引用的文献

[1]
Using clusterProfiler to characterize multiomics data.

Nat Protoc. 2024-11

[2]
Interplay between oncolytic measles virus, macrophages and cancer cells induces a proinflammatory tumor microenvironment.

Oncoimmunology. 2024

[3]
Ultrafast one-pass FASTQ data preprocessing, quality control, and deduplication using fastp.

Imeta. 2023-5-8

[4]
Tumor microenvironment-modulating oncolytic adenovirus combined with GSK-3β inhibitor enhances antitumor immune response against bladder cancer.

Front Immunol. 2024

[5]
Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance.

NPJ Precis Oncol. 2024-2-10

[6]
PD-L1 regulates inflammatory programs of macrophages from human pluripotent stem cells.

Life Sci Alliance. 2024-2

[7]
The tumor microenvironment shows a hierarchy of cell-cell interactions dominated by fibroblasts.

Nat Commun. 2023-9-19

[8]
Extending support for mouse data in the Molecular Signatures Database (MSigDB).

Nat Methods. 2023-11

[9]
Establishment and Characterization of Free-Floating 3D Macrophage Programming Model in the Presence of Cancer Cell Spheroids.

Int J Mol Sci. 2023-6-28

[10]
Dual CSF1R inhibition and CD40 activation demonstrates anti-tumor activity in a 3D macrophage- HER2 breast cancer spheroid model.

Front Bioeng Biotechnol. 2023-6-6

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索